Biogen Stock: Is BIIB Underperforming the Healthcare Sector?

Biogen Inc. (BIIB), headquartered in Cambridge, Massachusetts, with a market cap of $21.9 billion, is a leading biotechnology company specializing in developing and delivering innovative therapies. Known for its cutting-edge research and commitment to addressing unmet medical needs, Biogen focuses on neurological and neurodegenerative diseases, offering a diverse portfolio of treatments for conditions such as multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy, serving patients worldwide.

Companies valued at over $10 billion are typically classified as “large-cap stocks,” a category Biogen exemplifies through its strong market presence and leadership in the biotechnology industry. Biogen’s commitment to scientific innovation, quality, and patient-centered solutions underscores its position as a key player in advancing neuroscience and addressing the evolving needs of patients worldwide.